The 35-year-old software developer, based in China’s western metropolis of Chengdu ... which is prescribed to treat Type 2 diabetes. The drug company DK:NOVO.B NVO UK:0TDD also sells a ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation for obesity got the green light from the NMPA last month.

China has the world's largest diabetes population, with an estimated 148 million adult patients. More than 60 percent are overweight or obese. According to national figures released in 2020 ...

Maintaining sufficient sleep and going to bed earlier could help improve blood sugar control and reduce the risk of ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

This study provides critical evidence to guide policymakers and healthcare professionals in addressing the escalating health challenge posed by early-onset type 2 diabetes in China. Sex ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Objective This study aimed to identify body mass index (BMI) growth trajectories from birth to 24 months of age and examine ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...